Author: 59admin_north
The CEO of One-carbon Tx, Dr Ana Slipicevic, spoke with Yilmaz Biter at BioPitch about her path from oncology research to leading a first‑in‑class clinical program at One‑carbon Therapeutics.
The conversation offers a clear look at the decisions, data, and translational focus shaping the work of this pioneering biotech.
Read the full interview here.
Following Dr Giedrius Gasiunas’ presentation on the compact Cas12l CRISPR-Cas editor at the ASGCT Annual Meeting in Boston, a new GEN article highlights Caszyme’s development work on this promising genome editing platform.
Thanks to its compact size and C-rich PAM recognition, Cas12l opens exciting opportunities: expanding the CRISPR toolbox and positioning itself as a compelling alternative to Cas9.
Read the full GEN article here.
Australian biotech HaemaLogiX spoke to Scrip about its approach to the multiple myeloma space, and how it differentiates itself with new drug targets.
“There are a lot of drugs for multiple myeloma. It’s, in some ways, a very crowded space,” said CEO Chris Baldwin. “But we’re the only ones who are targeting KMA/LMA. Part of that is due to the extensive patent portfolio that we’ve established and developed over the course of the last 20 years. It means that when we come into the market, we have a very strong differentiator compared to anything out there,” Baldwin continued.
Read the full story here.
Fredrik Frejd, Chief Scientific Officer at Affibody, talked to Drug Discovery World about how the company’s radiotherapeutic candidate could address some of the limitations inherent in current approaches.
The field of targeted radiopharmaceuticals has witnessed remarkable growth in recent years, driven by blockbuster successes of Novartis’ Lutathera (lutetium Lu 177 dotatate) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which together generated over $2 billion in sales in 2024.
This commercial validation has sparked intense interest from both pharmaceutical companies and investors, with multiple billion-dollar acquisitions in the radiopharmaceutical space signalling confidence in the therapeutic approach.
Read the full story here.
CuraCell was recently featured in a wide ranging article in Labiotech on TIL therapy.
While many TIL developers are looking to treat melanoma first, the Swedish biotech is the first to take on prostate cancer. Its prime candidate CC-38 is being developed to address immunologically ‘cold’ solid tumors.
“While CAR-T therapies are clinically established in hematologic cancers, their efficacy in solid tumors – particularly immunologically cold tumors – remains unproven due to challenges such as limited tumor infiltration, antigen heterogeneity, and complex multi-step manufacturing processes. TIL therapies overcome these barriers by using naturally tumour-adapted T cells that can effectively infiltrate the tumour microenvironment and, through their polyclonal nature, recognize multiple tumour antigens, thereby reducing immune escape and improving outcomes in heterogeneous cancers,” said Jonas Båtelson, CEO and co-founder of CuraCell.
For more information on the TIL development landscape, read the whole article here.
In this interview with Clinical Trial Vanguard, Cereno Scientific CEO Sten Sorensen and CMO Rahul Argawal explain that epigenetic modulation of key pathophysiological pathways can do what vasodilation cannot: slow, halt, and potentially reverse the vascular remodelling that drives the relentless progression of pulmonary arterial hypertension (PAH).
Cereno's leaders also talked about the science behind Cereno's approach, the upcoming Phase IIb trial of lead asset CS1, and how this could impact on the lives of those living with PAH on a daily basis.
Read the full article here.
Drug Development & Delivery included an in-depth article on Affibody and its unique approach to radiopharma, and the clinical success of lead RLT candidate, ABY-271, which is currently being evaluated in a first-in-human clinical study in HER2 positive metastatic breast cancer.
Read the full article here.
The Board of Directors of Dicot Pharma AB intends to resolve on a rights issue of units, consisting of shares and warrants, corresponding to approximately SEK 210 million to finance the planned Phase IIb study with the drug candidate LIB-01.
The resolution on the Issue is intended to be made pursuant to the authorization proposed to the Annual General Meeting on May 6, 2026. The Issue, including complete terms and conditions, is expected to be resolved by the Board of Directors around May 8, 2026. The Issue is secured to 80 percent, corresponding to SEK 168 million, through subscription undertakings and guarantee commitments from existing shareholders as well as guarantee commitments from Schonfeld Global Master Fund LP, Anavio Capital Partners LLP and Vator Securities.
Read the full release here.
CuraCell TX AB (CuraCell) has announced the appointment of Dr Thomas Jaecklin and Prof Martin Forster to its Board of Directors, further strengthening the company’s leadership as it advances its mission to develop transformative cell-based therapies.
Read the full release here.
CuraCell CEO Jonas Batelson recently spoke to Jonathan Smith, a reporter for Mergermarket, about the companies plans for its next funding round to allow its TIL therapy trials to proceed.
Read the article here.